XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Exhibits ADCC Function that Synergizes with STING Pathway Activation and Contributes to Anti-tumor Responses
XMT-2056: A HER-2 Targeted Immunosynthen STING Agonist Antibody Drug Conjugate
August, 2022
XMT-2056: A HER-2 Targeted Immunosynthen STING Agonist Antibody Drug Conjugate
August, 2022
XMT-2056, a HER2-Targeted Immunosynthen STING-Agonist Antibody-Drug Conjugate, Binds a Novel Epitope of HER2 and Shows Increased Anti-tumor Activity in Combination With Trastuzumab and Pertuzumab
April, 2022
XMT-2056: Tumor-targeted Innate Immune Activation via a STING-agonist Antibody Drug Conjugate
October, 2021
XMT-2056, a Well-Tolerated, Immunosynthen-Based STING-Agonist Antibody-Drug Conjugate Which Induces Anti-tumor Immune Activity
April, 2021
Tumor Cell-intrinsic STING Pathway Activation Leads to Robust Induction of Type III Interferons and Contributes to the Anti-tumor Activity Elicited by STING Agonism
April, 2021